Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML

Reuters12-08

<a href="https://laohu8.com/S/CGEM">Cullinan Therapeutics</a> Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML

Cullinan Therapeutics Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted Fast Track designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597902-en) on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589354640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589354640","market":"nz","top_or_hot":-1,"title":"Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597902-en) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 23:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597902-en) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6dhyR4:1","article_id":"2589354640","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589354640","pubTimestamp":1765207869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cullinan Therapeutics Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia  and myelodysplastic syndrome . The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology  Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted Fast Track designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CGEM":"Cullinan Therapeutics","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Cullinan Therapeutics报告CLN-049治疗复发/难治性AML的有希望的1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":0.9,"NDAQ":0.9},"content_text":"Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML\n    \n\n        Cullinan Therapeutics Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted Fast Track designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597902-en) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589354640","isCrawlerRequest":true}